| Attribute |
Value |
| Founded |
2016 |
| Headquarters |
Oxford, UK |
| Ticker |
Private |
| CEO |
Dr. Antonin de Fougerolles |
| Funding |
Series B ($45M+), partnerships |
Evox Therapeutics is a biotechnology company developing exosome-based therapeutics using its proprietary DeliverEX™ platform. The company focuses on leveraging extracellular vesicles for targeted delivery of RNA therapeutics and proteins to the central nervous system, with potential applications in Parkinson's disease.
Evox's DeliverEX™ technology enables engineering of exosomes for therapeutic delivery:
- Surface Engineering: Decoration of exosome surface with targeting moieties (peptides, antibodies, fragments)
- Cargo Loading: Loading of therapeutic cargo including siRNA, miRNA, mRNA, and proteins
- Production: Scalable manufacturing from engineered producer cell lines
- Targeting: Receptor-mediated delivery to specific cell types
| Capability |
Description |
| Surface display |
Fusion of targeting peptides to exosome surface proteins (CD63, CD81) |
| Cargo loading |
Electroporation for nucleic acids; genetic engineering for protein cargo |
| BBB crossing |
Natural transcytosis capability of exosomes |
| Cellular specificity |
Engineering for targeting specific neuronal populations |
| Program |
Indication |
Stage |
Status |
| EV Platform |
CNS diseases |
Preclinical |
Partnering |
| EV Platform |
Rare disease |
Discovery |
Internal |
| Partnerships |
Multiple |
Various |
Active |
Evox has established partnerships with major pharmaceutical companies to leverage its platform for various CNS and non-CNS applications.
Evox's platform addresses key challenges in PD therapeutic development:
- SNCA silencing: Deliver siRNA targeting SNCA (alpha-synuclein gene) to reduce protein expression
- BBB delivery: Cross blood-brain barrier to reach substantia nigra neurons
- Targeted delivery: Surface engineering for specific delivery to dopaminergic neurons
- Gene therapy support: Enable mRNA delivery for therapeutic protein expression
flowchart TD
A["Therapeutic siRNA"] -->|"Loading"| B["Engineered Exosome"]
B -->|"Surface Targeting"| C["Targeted EV"]
C -->|"IV Administration"| D["Blood Stream"]
D -->|"Cross BBB"| E["Brain Parenchyma"]
E -->|"Receptor-Mediated Uptake"| F["Dopaminergic Neurons"]
F -->|"Gene Silencing"| G["Reduced α-Syn Expression"]
style G fill:#c8e6c9
- BBB crossing: Natural capability of exosomes vs. synthetic vectors
- Targeting: Precision delivery to specific neuronal populations
- Cargo flexibility: Can deliver siRNA, ASO, mRNA, and proteins
- Safety profile: Lower immunogenicity than many viral vectors
Evox has established multiple pharma partnerships:
- Eli Lilly: CNS partnership for RNA delivery
- Takeda: Rare disease applications
- Sanofi: Platform evaluation
- Platform validated in preclinical models
- Active partnering for CNS indications
- Manufacturing scale-up underway